美国2022年5月至2023年5月50岁以上成人猴痘的流行病学与临床特征
2022年5月至2023年5月美国报告约3万例猴痘病例,主要发生于年轻成年男性。分析比较了所有≥18岁成人猴痘病例的流行病学与临床结局,并按年龄组及JYNNEOS疫苗接种状态比较50岁以上成人结局。2022年5月10日至2023年5月17日,CDC共报告29,984例 probable 或 confirmed 猴痘成人病例,其中2,909例(9.7%)年龄>50岁,96.3%为顺性别男性。与18-50岁成人相比,>50岁成人免疫抑制状况(p<0.001)和HIV感染(p<0.001)患病率更高。>50岁猴痘成人中27.6%曾接种JYNNEOS疫苗;与未接种者相比,该组全身症状(p<0.001)、瘙痒(p<0.001)和住院(p=0.002)患病率更低。应鼓励所有有猴痘风险的成人接种目前推荐的JYNNEOS疫苗,无论儿童期天花疫苗接种状态如何。
要点
- 29,984例成人猴痘中2,909例(9.7%)年龄>50岁,96.3%为顺性别男性。
- >50岁成人较18-50岁成人免疫抑制状况和HIV感染患病率更高(p<0.001)。
- >50岁猴痘成人中27.6%曾接种JYNNEOS疫苗,该组全身症状、瘙痒和住院患病率更低。
核心结论
- >50岁成人猴痘病例占9.7%,其免疫抑制状况和HIV感染患病率高于18-50岁成人。
- >50岁猴痘成人中接种JYNNEOS疫苗者全身症状、瘙痒和住院患病率更低。
- 应鼓励所有有猴痘风险的成人接种目前推荐的JYNNEOS疫苗,无论儿童期天花疫苗接种状态如何。
研究设计与样本
- 分析比较了2022年5月10日至2023年5月17日CDC报告的29,984例 probable 或 confirmed 猴痘成人病例(≥18岁)的流行病学与临床结局,按年龄组比较,并在>50岁成人中按JYNNEOS疫苗接种状态比较结局。
主要发现
- 29,984例成人猴痘中2,909例(9.7%)年龄>50岁,其中96.3%为顺性别男性。
- 与18-50岁成人相比,>50岁成人免疫抑制状况患病率更高(p<0.001)。
- 与18-50岁成人相比,>50岁成人HIV感染患病率更高(p<0.001)。
- >50岁猴痘成人中27.6%曾接种JYNNEOS疫苗。
- 与未接种JYNNEOS疫苗的>50岁猴痘成人相比,接种者全身症状患病率更低(p<0.001)、瘙痒患病率更低(p<0.001)、住院患病率更低(p=0.002)。
临床怎么用
- 应鼓励所有有猴痘风险的成人接种目前推荐的JYNNEOS疫苗,无论儿童期天花疫苗接种状态如何。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
During May 2022-May 2023, approximately 30,000 mpox cases were reported in the United States, predominantly among young adult men. Persons aged >50 years might experience more severe mpox disease because of a higher prevalence of comorbidities. Conversely, they could have residual protection from childhood smallpox vaccination against monkeypox virus infection and severe mpox, as has been suggested by investigation of some previous mpox outbreaks. To examine the characteristics of mpox cases among adults aged >50 years, analysts compared mpox epidemiology and clinical outcomes among all adults aged ≥18 years, by age group. Further, outcomes were compared among adults aged >50 years by JYNNEOS vaccination status. During May 10, 2022-May 17, 2023, among 29,984 adults with probable or confirmed mpox reported to CDC, 2,909 (9.7%) were aged >50 years, 96.3% of whom were cisgender men. Compared with adults aged 18-50 years, adults aged >50 years had higher prevalences of immunocompromising conditions (p<0.001) and HIV infection (p<0.001). Among adults with mpox aged >50 years, 27.6% had received JYNNEOS vaccination; this group had lower prevalences of constitutional symptoms (p<0.001), pruritus (p<0.001), and hospitalization (p = 0.002) compared with those who had not received JYNNEOS vaccine. Currently recommended JYNNEOS vaccination among all adults at risk for mpox should be encouraged, irrespective of childhood smallpox vaccination status.
引用
- Eustaquio PC, Salmon-Trejo LAT, McGuire LC, et al. Epidemiologic and Clinical Features of Mpox in Adults Aged >50 Years - United States, May 2022-May 2023. MMWR Morb Mortal Wkly Rep. 2023. PMID: 37590262. doi:10.15585/mmwr.mm7233a3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。